Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Madison Asset Management LLC

Madison Asset Management LLC grew its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 33.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 62,363 shares of the company's stock after purchasing an additional 15,459 shares during the quarter. Madison Asset Management LLC's holdings in Genmab A/S were worth $1,221,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Barclays PLC grew its holdings in shares of Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company's stock valued at $52,000 after buying an additional 2,285 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Genmab A/S during the fourth quarter valued at $60,000. Aquatic Capital Management LLC acquired a new position in Genmab A/S during the fourth quarter valued at $114,000. Blue Trust Inc. lifted its position in Genmab A/S by 169.9% during the first quarter. Blue Trust Inc. now owns 7,413 shares of the company's stock valued at $145,000 after purchasing an additional 4,666 shares during the period. Finally, Versant Capital Management Inc lifted its position in Genmab A/S by 1,108.3% during the first quarter. Versant Capital Management Inc now owns 8,724 shares of the company's stock valued at $171,000 after purchasing an additional 8,002 shares during the period. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Trading Down 0.5%

Shares of Genmab A/S stock traded down $0.13 during trading hours on Monday, reaching $23.28. The stock had a trading volume of 198,305 shares, compared to its average volume of 1,465,684. The stock's 50 day moving average is $21.49 and its 200 day moving average is $20.80. The firm has a market capitalization of $14.93 billion, a PE ratio of 13.21, a PEG ratio of 7.11 and a beta of 0.94. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $28.56.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.08. Genmab A/S had a net margin of 35.11% and a return on equity of 18.08%. The firm had revenue of $715.00 million during the quarter, compared to the consensus estimate of $5.17 billion. As a group, sell-side analysts predict that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on GMAB. Wall Street Zen upgraded shares of Genmab A/S from a "hold" rating to a "buy" rating in a research report on Monday. HC Wainwright restated a "buy" rating and set a $37.00 target price (down from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th. Truist Financial boosted their target price on shares of Genmab A/S from $45.00 to $46.00 and gave the company a "buy" rating in a research report on Tuesday, July 8th. Finally, Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. One analyst has rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $37.80.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.